EMEA-000017-PIP01-07 - paediatric investigation plan

Albumin interferon alfa-2b

Key facts

• Active Substance:
  Albumin interferon alfa-2b
• Therapeutic area:
  Gastroentology-Hepatology
• Decision number:
  P/23/2008
• PIP number:
  EMEA-000017-PIP01-07
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  Treatment of chronic hepatitis C
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Novartis Europharm Limited

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  23/05/2008

Decision

P/23/2008: European medicines agency decision of 23 May 2008 on the application for agreement of a Paediatric Investigation Plan for albumin interferon alfa-2b, EMEA-000017-PIP01-07, in accordance with Regulation (EC) No...

AdoptedLegal effective date: 17/06/2008Reference Number: EMEA/258718/2008